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A B S T R A C T
Ketosis is a metabolic state in which the body uses ketones derived from breakdown of fatty acids as the primary mitochondrial fuel source instead of glucose. In
recent years an accumulation of evidence for the beneﬁcial eﬀects of the ketotic state on the brain have heightened interest in its potential for use in neurological
conditions. The ketogenic diet (KD) induces ketosis and is an eﬀective treatment for medically resistant epilepsy. There is signiﬁcant comorbidity between epilepsy
and bipolar disorder (BD) and both conditions are treated by anti-convulsant drugs. In addition, reports on bipolar disease online fora have highlighted subjective
mood stabilization eﬀects associated with the KD. These KD reported eﬀects could be explained if there was a disorder in the conversion of pyruvate into Acetyl-CoA
(and subsequent impairment of oxidative phosphorylation) which was bypassed by ketones providing an alternative substrate for oxidative phosphorylation. This is
consistent with growing evidence that mitochondrial dysfunction plays a causal role in BD and explains the reported TCA cycle dysfunction and elevated pyruvate
levels in BD. Reduced levels of ATP aﬀects the normal operation of the Na, K-ATPase in the brain with diﬀering levels of reduction either leading to reduced neuronal
action potential and inhibition of neurotransmitter release (consistent with the depressed state in BD) or increased neuronal resting potential and hyper-excitability
(consistent with a [hypo]manic mood state). We hypothesize that the mitochondrial dysfunction is due to a disorder of the Pyruvate Dehydrogenase Complex (PDC)
and/or Mitochondrial Carrier Protein (MCP) shuttle which moves intracellular pyruvate into mitochondria. The resultant reduction in ATP generation could explain
mood instability and cycling in BD (through mechanisms such as those delineated by Mallakh and Peters). This proposed novel causal pathway could explain mood
de-stabilization in BD and the reported positive eﬀects of KD. If true, this hypothesis would suggest that there should be increased research attention to PDC (and in
particular the E1 alpha subunit) as potential therapeutic targets and further study of a possible role of KD in BD to improve mood stability. Experimental approaches,
such as through a clinical trial of KD on mood stabilization in BD, are required to further investigate this hypothesis.
Introduction
Ketosis is a metabolic state where the body uses ketones derived
from breakdown of fatty acids as the primary fuel source instead of
glucose. In recent years an accumulation of evidence for the beneﬁcial
eﬀects of the ketotic state on the brain have heightened interest in its
potential for use in neurological conditions. Such beneﬁts include im-
provements in cerebral metabolism [1] changes in neurotransmitter
levels [2,3], increase of mitochondrial glutathione levels [4], increased
NADH oxidation [5], increased mitochondrial biogenesis and other
signiﬁcant neuroprotective eﬀects [6].
Therapeutic use of the ketogenic diet in refractory epilepsy
Ketosis is induced primarily through fasting or adherence to the
ketogenic diet (KD) which is a high fat, very low carbohydrate and
adequate protein dietary program. The KD is currently used as an ef-
fective treatment for medically resistant epilepsy with its eﬀect con-
ﬁrmed through meta-analysis of clinical trials. Through strict adherence
to the diet long term seizure reduction can be achieved [7,8]. Several
proposed mechanisms of seizure prevention are summarized by
Simeone [9], however there is as yet no consensus as to the mode of
action.
The most signiﬁcant biological eﬀect of the KD is the metabolic
switch from glucose as the primary fuel substrate for ATP production to
ketones as the primary mitochondrial fuel. The ketotic state has been
shown to increase both mitochondrial ATP production and the opening
of K(ATP) channels in neurons [10]. Several researchers suggest that
the profound mitochondrial eﬀects of the ketotic state lead to seizure
reduction through the re-establishment of sodium-potassium pump (Na,
K-ATPase) function in neurons [10]. Ketone levels have been found to
be associated with the anticonvulsant eﬀect, with this action being
reversed rapidly by intravenous infusion of glucose [11]. This may in-
dicate that an underlying mechanism such as the Na, K-ATPase which
responds rapidly to changes in cellular energy is implicated in epileptic
seizures. Eliminating metabolically sensitive K(ATP) channels abolishes
the anti-convulsant eﬀect of ketogenic diet [10].
Ketosis and bipolar disease (BD)
There is signiﬁcant comorbidity between epilepsy and bipolar dis-
order (BD) and both conditions are treated by anti-convulsant drugs
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[12,13]. Both conditions are characterized by an episodic nature, [14]
altered mitochondrial energy production [15] and show evidence of
functional brain abnormalities as well as altered neuronal ion gradients
[14]. A review of bibliographic databases on ketosis and BD identiﬁed
only two small reports [16,17]. In one report the subject failed to
achieve a detectable level of ketones [16], in the other both subjects
reported signiﬁcant mood stabilization exceeding that achieved
through medication [17]. However, a google search of online fora
identiﬁed many testimonials from BD forums with dramatic reports of
improvement. A controlled analysis of these reports concluded that the
association between adoption of a ketogenic diet and improved mood
stabilization in BD is worth further investigation and is not fully ex-
plained by selection and reporting biases in self-reported observational
data [18].
The ketogenic diet and the mitochondrial dysfunction hypothesis
for BD
Recent research evidence has strengthened support for the hy-
pothesis that mitochondrial dysfunction has a causal role in BD. This
has recently been elaborated in detail by Kato [19] and Kim [20] who
highlight the MRI, biochemical and genetic data which support this
hypothesis. It has been noted that mitochondrial dysfunction would be
expected to inﬂuence neural processes which could underlie BD such as
altered sodium/calcium dynamics and signaling and increased creation
of reactive oxygen species with resulting oxidative stress [20]. Silver
suggests that altered neuronal sodium/calcium dynamics may indicate
that there is a minimum ATP requirement for full function of the neu-
ronal Na, K-ATPase which is not met under inhibition of either glyco-
lysis or oxidative phosphorylation [21]. The resultant loss of Na, K-
ATPase function leads to large calcium inﬂux to neurons with resultant
glutamate excitotoxicity and neuronal apoptosis, both of which play a
central role in neurodegeneration in BD [21].
Mitochondrial dysfunction as the cause of mania and depression in
BD
As early as 1983 Mallakh et al hypothesized that Na, K-ATPase
dysfunction could underlie both manic and depressed states in BD [22].
He noted that a modest reduction of Na, K-ATPase function in the brain
can lead to a hyper-excitable state by bringing the resting potential of
neurons closer to the threshold for activation. Elevated calcium in the
neuron due to decreased rate of clearance would also increase the
duration of neurotransmitter release. This state may explain both the
mood state and the elevated neuronal calcium observed in mania.
Further reduction in Na, K-ATPase function would bring the resting
potential even closer to the threshold for activation yet decrease the
amplitude of the action potential with resultant inhibition of neuro-
transmitter release. This state of impaired neuronal activity may con-
tribute to the low-energy depressed state in BD. Brietzche [23] recently
highlighted Peters [24] “Selﬁsh Brain” hypothesis which describes a
similar dynamic where neurons enter an excitatory state with release of
glutamate under modest reduction of ATP and a refractory state under
larger yet non-critical reduction in ATP levels.
Silver [21] demonstrated that the ATP threshold for normal Na, K-
ATPase function can only be achieved through the combination of
oxidative phosphorylation and glycolysis. In his study impairment of
oxidative phosphorylation of the kind commonly observed in BD led to
reduction of Na, K-ATPase function and calcium accumulation in neu-
rons.
Mitochondrial dysfunction and pyruvate dehydrogenase
Impairment of oxidative phosphorylation is a key component of the
reported mitochondrial dysfunction in BD but the source of this dys-
function is currently unknown.
Metabolomic studies have shown disruption of the TCA cycle in BD
Fig. 1. Ketone body D-beta-hydroxybutyrate bypasses a block in the PDH (pyruvate to acetyl CoA) in the cytoplasm and provides acetyl CoA to the TCA Cycle.
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and increased levels of pyruvate [25] We hypothesize that the increased
levels of pyruvate and consequently lactate (as a product of increased
glycolysis) commonly observed in BD are caused by a dysfunction in the
Pyruvate Dehydrogenase Complex resulting in impaired ability to uti-
lize pyruvate within the TCA cycle [25].
In a state of ketosis, high plasma levels of ketones such as beta-
hydroxybutyrate act as an alternative energy source and can supply
acetyl coA directly to the TCA cycle providing an alternative pathway
to that from pyruvate (see Fig. 1). The reports of the positive eﬀects of
the ketogenic diet on mood stabilization in BD are consistent with a
reduced formation of acetyl CoA from pyruvate which is bypassed by
this alternative source of acetyl CoA from ketones. This, in turn, implies
reduced activity of mitochondrial pyruvate dehydrogenase (PDH) or
reduced carriage of intra-cellular pyruvate transport across the mi-
tochondrial membrane by mitochondrial carrier proteins (MPC) – (see
Fig. 1).
There is some support for this interpretation since the ketogenic
state has been shown to restore the function of the TCA cycle. This has
been well demonstrated in cases of PDH (also known as PDC) deﬁciency
and the KD is the standard care for these conditions [26]. KD has also
been reported to maintain ATP production with resultant neuropro-
tective eﬀects under hypoxic, glycolytic conditions where oxidative
phosphorylation is inhibited [27]. In these circumstances the pyruvate
dehydrogenase complex is de-activated by pyruvate dehydrogenase
kinases [28]. In PDH deﬁciency dysfunctional PDH kinases create an
inhibition of PDH complex function which is prolonged. Most reported
cases of PDC dysfunction to date have been shown to be due to the
inactivation of the PDH E1 alpha subunit, which contains a sulfhydryl
enzyme vulnerable to damage from reactive oxygen species [29]. This
enzyme acts as a phosphorylation switch which can be aﬀected by
various factors, including trauma, ageing and genetic mutation [29,30]
Ketones bypass the PDH complex to provide an alternative substrate for
the TCA cycle and so mitochondrial function can be restored even under
such conditions. It is worth noting that in cases of traumatic brain in-
jury KD has been reported to show similar metabolic and neuropro-
tective eﬀects [31]. Tissue speciﬁcity of these eﬀects to the brain is
likely explained by the existence of at least 4 isozymes of pyruvate
dehydrogenase kinase (PDK), with PDK3 being the principal kinase
regulating PDH activity in the brain in mice [32].
PDH complex dysfunction unites several lines of evidence in the
etiology of BD. As a mechanism, it provides biologically plausible ex-
planations for diverse observations of mitochondrial dysfunction, oxi-
dative stress, altered neuronal sodium/calcium, increased pyruvate and
lactate levels, excitotoxicity and the reported eﬀectiveness of ketogenic
diet which merit further study. The cascade of eﬀects resulting from
PDH dysfunction are detailed in Fig. 2.
Despite the KD being a commonly recommended intervention in
online BD forums with many reports of beneﬁt, there are currently no
randomised controlled trials of the KD in BD. In addition, there are no
studies, to our knowledge, directly assessing PDC function in BD pa-
tients. The available data on the association between ketogenic diet and
BD are observational and very limited (and hence ﬁndings are not yet
replicated). There is a need for experimental data to explore whether
there is any evidence for causal associations. It is interesting to note,
however, that while there is no direct research into PDC function in BD
the 2 primary biomarkers of PDC dysfunction (elevated CSF lactate and
pyruvate) are also 2 of the most commonly observed biomarkers noted
to be increased in BD [17]. Additionally, PDC dysfunction is a mi-
tochondrial disorder and these have been shown to be associated with a
greatly increased risk of BD [33].
Most published data on PDC dysfunction describe the rare, severe
form which has onset in early childhood. The features of classic PDC
dysfunction would not be expected in our model which hypothesizes a
gradual long-term reduction of PDC function due to genetic and/or
environmental factors. Most cases of severe PDC dysfunction are due to
a mutation in PDHA1 aﬀecting a major subunit of the enzyme [33]. This
occurs rarely but has a severe phenotype. However, PDC is one of the
largest enzyme complexes in humans and many other genetic mutations
and variants are described, leading to a wide range of phenotypes.
These include late onset PDCDs [34]. The PDC is vulnerable to damage
from several environmental and biological factors as it contains a
sulfhydryl enzyme which is damaged by reactive oxygen species. PDC
activity reduces with age due to a combination of these causes [35].
There are few studies of later onset forms of PDC dysfunction and it is
unknown what nature of symptoms would be expected in such cases.
This pattern of a rare severe deleterious mutation having a severe
phenotype but more frequent less deleterious mutations/variants in the
same gene with less severe phenotypic consequences is common in
Mendelian conditions.
A recent publication describes the development of a brain-speciﬁc
PDHA1 knockdown mouse model [36]. This study demonstrated that
the resulting metabolic defects in brain glucose metabolism were as-
sociated with the joint presence of both “episodic neuronal hyper-
excitation” [seizures] and “reduced basal cerebral electrical activity”.
These defects were reversed in part by intraperitoneal injection of
acetate, a downstream metabolite. These ﬁndings were in the context of
a study of epilepsy but they provide support for the general mechanisms
in our hypothesis for BD, including for the action of ketone bodies
generated by individuals on a ketogenic diet.
Conclusion
We hypothesize that in some cases of BD dysfunction of Pyruvate
Dehydrogenase and/or Mitochondrial Carrier Proteins may be an im-
portant causal pathway which could explain mood destabilisation and
the reported positive eﬀects of KD. The E1 alpha subunit dysfunction is
the most common reported source of PDC dysfunction and contains a
sulfhydryl group vulnerable to proton donors making it liable to da-
mage. Inability to convert pyruvate into Acetyl-CoA leads to impair-
ment of oxidative phosphorylation and explains the commonly ob-
served elevated pyruvate levels in BD. In response to this dysfunctional
state the body shifts primarily to glycolytic energy production to gen-
erate ATP. High levels of lactate are then generated as a byproduct of
glycolysis – another key biomarker of BD. The levels of ATP generated
by glycolysis-only have been shown to be incapable of sustaining
normal operation of the Na, K-ATPase in neurons. Under conditions of
severe but non-critical lack of ATP this leads to decreased action po-
tential in neurons, decreased neurotransmitter release and the de-
pressed state in BD. Under conditions of less severe lack of ATP, in-
hibition of Na, K-ATPase function results in an excitatory state in the
brain caused by the resting potential of neurons moving closer to the
threshold for activation. This under-regulated state leads to calcium
ﬂux through neurons, glutamate excitotoxicity, (hypo)manic mood
state and neuronal apoptosis.
The next step forward would be to develop experimental approaches
to further investigate these observational descriptive data. This could
be done through the conduct of a clinical trial of the KD in BD with
robust measures of mood stabilization as trial outcomes.
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Fig. 2. PDH dysfunction leading to, impaired oxidative phosphorylation, reduced ATP production, reduced Na, K-ATPase activity and bipolar mood states.
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